

1 **SARS-CoV-2 testing in the community: Testing positive samples with the TaqMan SARS-CoV-2**
2 **Mutation Panel to find variants in real-time**

3 Fiona Ashford¹, Angus Best¹, Steven Dunn², Zahra Ahmed¹, Henna Siddiqui¹, Jordan Melville¹, Samuel
4 Wilkinson², Jeremy Mirza², Nicola Cumley², Joanna Stockton², Jack Ferguson³, Lucy Wheatley³,
5 Elizabeth Ratcliffe⁴, Anna Casey⁴, Tim Plant¹, The COVID-19 Genomics UK (COG-UK) Consortium⁵,
6 Joshua Quick², Alex Richter¹, Nicolas Loman², Alan McNally².

7 ¹Clinical Immunology Service, Institute of Immunology and Immunotherapy, College of Medical and
8 Dental Science, University of Birmingham, United Kingdom.

9 ²Institute of Microbiology and Infection, College of Medical and Dental Science, University of
10 Birmingham, Birmingham, United Kingdom.

11 ³Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of
12 Birmingham, Birmingham, United Kingdom.

13 ⁴Department of Clinical Microbiology, University Hospitals Birmingham NHS Foundation Trust, Queen
14 Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, United Kingdom.

15 ⁵<https://www.cogconsortium.uk> (Full list of consortium names and affiliations are in the appendix)

16 Corresponding author: A.McNally.1@bham.ac.uk

17

18 **ABSTRACT**

19 Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages, however there can
20 be limitations due to sequence drop-out when used to identify specific key mutations. Recently,
21 Thermo Fisher Scientific have developed genotyping assays to help bridge the gap between testing
22 capacity and sequencing capability to generate real-time genotyping results based on specific variants.
23 Over a 6-week period during the months of April and May 2021, we set out to assess the Thermo
24 Fisher TaqMan Mutation Panel Genotyping Assay, initially for three mutations of concern and then an
25 additional two mutations of concern, against SARS-CoV-2 positive clinical samples and the
26 corresponding COG-UK sequencing data. We demonstrate that genotyping is a powerful in-depth
27 technique for identifying specific mutations, an excellent complement to genome sequencing and has
28 real clinical health value potential allowing laboratories to report and action variants of concern much
29 quicker.

30 **Keywords:** SARS-CoV-2, variants of concern, genotyping, genome sequencing, real-time, SNPs

31

32 INTRODUCTION

33 Viruses mutate and SARS-CoV-2 is no exception. As the COVID-19 pandemic continues around the
34 world, mutations are naturally occurring resulting in the emergence of divergent clusters / variants
35 containing sets of mutations. These clusters/variants have differing prevalence in different
36 geographical regions, likely in response to changing immune profiles of the human population **(1)**.
37 Movement of people enabled by global air travel, allow these variants to spread and mutate further
38 under differing selection pressures. In the United Kingdom, the Alpha variant (B.1.1.7), first identified
39 in Kent, rapidly swept to dominance by December 2020 **(2)**. In April 2021, the Delta variant (B.1.617.2),
40 first identified in India, rapidly outcompeted the Alpha variant to become dominant in a matter of
41 weeks **(3)**. The geographical location where these variants emerged is not relevant **(4)**, rather it is the
42 specific mutations present which greatly impacts virus characteristics including transmissibility and
43 antigenicity, where mutations of significance have been identified in the SARS-CoV-2 Spike Protein of
44 these variants of concern (VOC), that contribute to enhanced transmission and/or immune invasion
45 **(5)**. Other VOC have been identified and characterised, including both Beta (B.1.351 – first identified
46 in South Africa) and Gamma (P.1 – first identified in Brazil) **(5)**.


47 Previously at the University of Birmingham, we set up a SARS-CoV-2 modular testing facility at the
48 request of the United Kingdom Department of Health and Social Care **(6)**. Our PCR assay of choice was
49 the 3-target design (ORF1ab, S and N genes) TaqPath COVID-19 CE-IVD RT PCR Kit, where target areas
50 are unique to SARS- CoV-2 to reduce detection of other coronaviruses and compensate for virus
51 mutations. Initially, we detected all three genes in SARS-CoV-2 samples, however, during November
52 2020, we along with other laboratories using the same PCR assay, started to notice a drop-off in the
53 detection of the S-gene and then a rapid rise in this S-gene target failure (SGTF) in early December
54 2020 **(7)**. From discussions with the University of Birmingham genome sequencing laboratory (as part
55 of the COG-UK Consortium) and as confirmed by other laboratories, it was demonstrated that S-gene
56 did amplify, therefore confirming this gene was still present, but was not being detected using the

57 TaqPath COVID-19 assay. This was attributed to a 6-bp deletion ($\Delta 69/70$) in the middle of the S-gene
58 where the fluorescent specific probe binds, thus negating the probe's ability to fluoresce (8).
59 Simultaneously, these findings of a new VOC were reported by our laboratory and multiple testing
60 facilities across the UK, where this finding identified the VOC B.1.1.7 (Alpha variant). Although SGTF
61 identification with the Thermo Fisher TaqPath RT-qPCR assay was not intentional, this observation
62 with this PCR assay allowed us and other COVID-19 testing facilities to use this assay as an accurate
63 epidemiological tool to track the rise, spread and dominance of this VOC in the UK. By April 2021,
64 COVID-19 TaqPath PCR testing facilities, including our laboratory, noted an increasing number of
65 samples without SGTF, where the 3 target genes were amplifying and upon genome sequencing
66 analysis these samples were identified as the Delta (B.1.617.2) variant (9).

67 To better understand viral transmission and evolution and to inform public health responses and
68 vaccine development, genomic sequencing is essential. In March 2020, the COVID-19 Genomics UK
69 Consortium (COG-UK) was created for this purpose (10). To date, COG-UK have sequenced over
70 1,100,000 SARS-CoV-2 samples, providing a vast amount of data to the global COVID-19 response. This
71 yields crucial information about the number of variants circulating in the population and possible lines
72 of transmission, however, sequencing can be timely, costly and in some cases full coverage of the virus
73 is not possible.

74 Recently, Thermo Fisher have developed genotyping assays to help bridge the gap between testing
75 capacity and sequencing capability to receive results in real-time, so in addition to our modular system
76 for COVID-19 testing, we decided to build into our work-flow the Thermo Fisher TaqMan™ SARS-CoV-
77 2 mutation panel (Figure 1). Here we present our data showing that the TaqMan genotyping assays
78 identify variants in all samples tested with zero failure rate, and that often the assay confirms
79 mutations in a viral isolate that cannot be definitively identified from genome sequence data alone.
80 We conclude that the genotyping assay is an excellent complement to genome sequencing efforts and

81 allows rapid, point-of-testing determination of the presence of any genetic variant for SARS-CoV-2 for
82 which an assay can be designed.



83

84 **Figure 1.** Workflow for Thermo Fisher TaqMan™ SARS-CoV-2 Mutation Panel Assay. Blue workflow: Protocol used
85 to detect SARS-CoV-2. Orange workflow: Protocol using SNP assays to confirm mutations associated with SARS
86 CoV-2 emerging variants.

87 METHODS

88 Patient samples

89 500 Nasopharyngeal Pillar 1 swab samples in Virus Transfer Medium (VTM) samples were sent to the
90 University of Birmingham during April and May 2021 from Birmingham Health Trust Hospital. SARS-
91 CoV-2 positive samples from the University of Birmingham Lateral Flow testing site were also sent and
92 archived Pillar 2 SARS-CoV-2 samples previously identified in February 2021 at the University of
93 Birmingham Turnkey laboratory were also utilised. The use of anonymised samples in this study was

94 allowed under ethics gained to aid assay development (NRES Committee West Midlands - South
95 Birmingham 2002/201 Amendment Number 4, 24 April 2013).

96 **RNA extraction**

97 RNA was extracted from 200 µl of patient sample using the Thermo Fisher MagMax Viral/Pathogen II
98 Nucleic Acid isolation kits with MagMax magnetic beads and MS-2 phage internal control, using the
99 automated Thermo Fisher Kingfisher Flex Magnetic Particle Processor (11).

100 **TaqPath™ COVID-19 assay**













101 Reactions were prepared using the Thermo Fisher TaqPath™ COVID-19 CE-IVD RT-PCR Kit protocol
102 (12). RT-PCR of reactions were performed using the Applied Biosystems™ QuantStudio™ 5 Real-Time
103 PCR Instrument. Subsequent EDT files were transferred to a computer with QuantStudio™ Design and
104 Analysis Desktop Software v2.5.1 for analysis of exponential curves. The TaqPath™ COVID-19 assay
105 co-amplifies three target genes: ORF1ab, N-gene and S-gene. Results were classified as positive with
106 respect to at least 2 single-target genes (Orf1ab, N-and S-) provided the raw RT-Ct values were below
107 37 for single gene target signals. Bacteriophage MS2 RNA was added to each sample as an internal
108 positive control for each sample and to monitor potential sample inhibition. The SGTF of the
109 TaqPath™ COVID-19 CE-IVD RT-PCR Kit was considered a proxy for the presence of Δ69/70 in the S
110 gene of SARS-CoV-2.

111 **TaqMan™ SARS-CoV-2 Mutation Panel Workflow**

112 Sample inclusion for the mutation assay required RNA extracts from positive samples ($Ct \leq 30$) for the
113 TaqMan™ SARS-CoV-2 Mutation Panel workflow. From our pool of positive samples 185 were
114 randomly selected for the mutation panel assay following the assay workflow (Figure 1). Samples
115 containing S-gene single-target failure (SGTF) were included in the assay as long as ORF1a and N-gene
116 Ct values were within range as there was no compromise of assay accuracy.

117 **Designing a Genotyping Panel for the Mutation Assay**

118 TaqMan probes specific to SNPs found in variants known to be circulating widely within the United
 119 Kingdom around March-May 2021 were used in this study. S-gene mutations chosen were N501Y,
 120 E484K, K417N, P618R and L452R (Figure 2). Probes detect both the reference and mutation sequences
 121 of SARS-CoV-2. Reporter dye information for the TaqMan™ SARS-CoV-2 Mutation Panel is represented
 122 in the assay context sequence, which is the nucleotide sequence surrounding the mutation site in the
 123 SARS-CoV-2 reference genome (hCoV-19/Wuhan/2019; GISAID EPI_ISL_402124). The variant allele is
 124 detected by FAM™ dye and the reference allele is detected by VIC™ dye.

Mutation	Associated Variant	Phenotype
K417N	Beta (B.1.351) B.1.1.33	 
K417T	Gamma (P.1)	 
E484K	Beta (B.1.351) Gamma (P.1) Eta (B.1.525) B.1.1.33, B.1.1.207	 
N501Y	Alpha (B.1.1.7) Beta (B.1.351) Gamma (P.1) B.1.177, B.1.258, B.1.1.33	 
L452R	Delta (B.1.617.2) Kappa (B.1.617.1) B.1.617.3, Epsilon (B.1.427, B.1.429)	 
P681R	Delta (B.1.617.2) Kappa (B.1.617.1)	 

Key:



125 **Figure 2.** Thermo Fisher Mutation Panel Assay targets with associated SARS-CoV-2 variants and phenotype.

126 Presence of SGTF and N501Y was indicative of the Alpha variant, Beta variant was defined with the
127 presence of K417N, E484K and N501Y, Gamma as E484K and N501Y without the presence of K417N,
128 while the presence of L452R and P681R was indicative of the Delta variant.

129 Positive controls for both the Original SARS-CoV-2 sequence and chosen SNP mutations were used in
130 the assay. The AcroMetrix™ coronavirus 2019 (COVID-19) RNA control (Low Positive Control),
131 prepared using full length genomic RNA from SARS-CoV-2, was used as a positive control for SARS-
132 CoV-2. A plasmid control containing mutation sequences for N501Y, E484K and K417N was used as a
133 positive control for SNP mutations. However, at the time of running these experiments a plasmid
134 control for mutations P681R and L452R was unavailable.

135 RT-PCR reaction mix was prepared as per the assay protocol (12). For samples with Ct values < 30, 5
136 µl of RNA was added to the reaction, for samples with Ct < 16, 2.5 µl of RNA was added to the reaction.
137 Reactions and real- time PCR program were set up according to the mutation panel assay protocol
138 (13).

139 **Library preparation and sequencing**

140 Library preparation of positive SARS-CoV-2 samples (cycle threshold <30) was performed using the
141 nCoV-2019 LoCost Sequencing Protocol version 3 (14), using normalised primers (New England
142 Biolabs) for the V3 ARTIC primer scheme (ARTIC network) (15). Sequencing was performed on a
143 MinION flow cell (R9.4.1) run on a GridION sequencing device (Oxford Nanopore Technologies).

144 The ARTIC network “nCoV-2019 novel coronavirus bioinformatics protocol” (16) was used to process
145 the raw sequencing data including genome assembly and variant calling using nanopolish 0.11.3 (17).

146 The genotyping was then performed using a nextflow pipeline
147 (<https://github.com/BioWilko/genotyping-pipeline>). Briefly; genotypes were called using aln2type
148 (<https://github.com/connor-lab/aln2type>) utilising custom variant definition files for each mutation
149 (included in repository), and lineages were called using Pangolin (18).

150 **Data Analysis**

151 Results were plotted as Allelic Discrimination Plots using the QuantStudio Design & Analysis v2.5 with
152 the Genotyping Analysis Module.

153 **RESULTS**

154 **Allelic discrimination plots show clear discrimination between Wild-type samples and Mutation**
155 **samples using QuantStudio Design & Analysis**

156 The Design & Analysis software genotype calling algorithm is designed for diploid organism genotype
157 calling. The reference allele cluster should be called as homozygous allele 1, the variant allele cluster
158 should be called homozygous_allele2 and heterozygous_allele1/allele2. Samples are called as either
159 allele1/allele1 (ref/ref, WT), Allele2/Allele2 (mut/mut), Allele1/Allele2 (ref/mut) and no amplification
160 (Figure 3A), thus allowing for clear and simple classification of results.

161 Each probe is labelled with VIC dye to detect the reference (WT) sequence and FAM dye to detect the
162 mutation sequence, which has one nucleotide difference. This allows clear discrimination on a cluster
163 plot between WT and mutation samples, as seen with the AcroMetrix control (reference sequence)
164 and plasmid control containing the mutation sequence, Figure 3B.


165 Where input samples have similar Ct values they appear as clusters on the discrimination plot, as seen
166 in the mut/mut samples (Figure 3B) or in the case of a range of Ct values, samples are dispersed
167 along/up the axis as seen in ref/ref samples (Figure 3B and C). We were able to detect samples with
168 Ct's varying from 12 to 29, in respect to ORF1ab, N-gene and S-gene. In one case we could detect
169 mutations with Ct value 33, albeit with slightly reduced sensitivity. Samples with high viral load cluster
170 in the upper x/y-axis and low viral load in the lower x/y-axis.

171 Independent mutations that are located next to one another in SARS-CoV-2 virus genome, such as
172 P681R and P681H, can complicate genotype analysis, as probes of an assay for one mutation will fail
173 to bind to viral sequences that contain other adjacent mutations. Mutations under the probe can

174 appear as ref/mut and slope away from ref/ref or mut/mut samples, cluster along the X-axis, near to
175 the NTCs, thus exhibiting weak amplification due to the probes non-specific activity, Figure 3C.
176 Genotyping calls can manually be adjusted to 'no amp', or two separate assays run such as P681R and
177 P681H to compare and facilitate accurate genotype analysis. If it is not possible to make a call, then
178 further characterisation by genome sequencing would be necessary.

(A) Assay Result/Call:

● Allele1/Allele1 (ref/ref) ● Allele2/Allele2 (mut/mut) ● Allele1/Allele2 (ref/mut) ● No Amplification




179

180 **Figure 3.** Mutation Assay Results viewed using QuantStudio Design & Analysis software with the
181 Genotyping Analysis Module. **(A)** Assay results are 'called' in 4 colours according to their outcome. Red
182 indicates allele1/allele1 (ref/ref) for WT, blue allele2/allele2 (mut/mut) for mutation present, green
183 refers to allele1/allele2 (ref/mut) and orange showing no amplification. **(B)** Allelic discrimination plot
184 showing clear discrimination between wild type (WT) samples (red dots along the x-axis) and the

185 mutation samples (blue dots along the y-axis) with high and low viral loads. **(C)** Allelic discrimination
186 plot showing an example of a ref/mut sample (green dots). Abbreviations: Ct (Cycle threshold).

187 The Mutation Panel Assay is extremely effective at identifying mutations in laboratory samples

188 All samples run through the mutation panel assay produced a result, with either mutation present,
189 absent or reference/mutation, indicating another mutation within that SNP was present. Input
190 samples had varying Ct values (Ct 12-29) with regards to each of the three single-target genes Orf1ab,
191 N gene and S gene (Supplementary data 1). Using the Orf1ab gene as marker for Ct distribution across
192 a Ct value group, good distribution of different Ct values was observed (Figure 4). RNA quality was not
193 measured, and in some cases, samples had been stored at -80°C for up to 2 months and through no
194 more than 2 freeze/thaw cycles. However, no effect on the performance of the mutation assay was
195 observed. Furthermore, we also noted that for positive samples Ct ≤ 18 RNA was added at 2.5ul instead
196 of 5ul into the Mutation Panel PCR reaction, therefore, allowing more RNA to be archived.



197
198 **Figure 4.** Distribution of TaqPath COVID-19 PCR Ct values for the Orf1ab gene. The Y-axis indicates the number
199 of samples SARS-CoV-2 positive for the Orf1ab gene. The X-axis is grouped into ranges for Ct values up to and
200 including 30. Abbreviations: Ct (Cycle threshold), Orf1ab (Open reading frame 1ab).


201 All samples run through this assay were sent for sequencing onsite at the University of Birmingham as
202 part of COG-UK. This provided us with the ability to compare the mutation panel assay results with

203 that of genome sequencing. By cross referencing the genome sequencing results for each SNP we
 204 could identify whether the mutation assay correctly calls each SNP mutation. Our data shows that for
 205 all samples, where sequencing data was available, the mutation panel is in 100% agreement (Figure
 206 45A - Also refer to Supplementary Data 1 for complete data set for all samples run). While Nanopore
 207 sequencing may miss a SNP mutation (Figure 5B), the mutation assay can identify this. This is likely
 208 due to the RNA quality and platform used for sequencing, but highlights the importance of the
 209 genotyping assay for rapid identification and subsequent action.

(A)

Accession ID	Sequencing Coverage (%)	Lineage	Mutation Panel Result					Nanopore Sequencing Result				
			K417N	E484K	N501Y	L452R	P681R	K417N	E484K	N501Y	L452R	P681R
ERS6456639	98	B.1.617.2	N	N	N	Y	Y	N	N	N	Y	Y
ERS6369109	99	B.1.1.7	N	Y	Y	N	ref/mut	N	Y	Y	N	N
ERS6277913	98	B.1.351	Y	Y	Y	N	N	Y	X	X	X	N
ERS6334604	98	B.1.1.7	N	N	Y	N	ref/mut	N	N	Y	N	N
ERS6814017	99	B.1.1.77	N	N	N	N	N	N	N	N	N	N
ERS6457354	87	B.1.1.7	N	N	Y	N	N	N	N	Y	N	X

210



211

212 **Figure 5. (A)** Example of mutation assay results compared with Nanopore sequencing results from a selection of
213 samples run through the assay. All results for all samples run are included in Supplementary Data 1. Orange
214 Square 'N' = mutation not present; Green Square 'Y' = mutation present; White 'ref/mut' = mutation present on
215 one allele only. The Red square 'X' indicates that there was not sufficient coverage of that SNP after sequencing.
216 **(B)** Percentage comparison results of all mutation assay results and corresponding Nanopore sequencing data.
217 Green Bars (Mutation Assay) = Percentage (%) SNP agreement when compared to the corresponding sequencing
218 data. Blue Bars (Sequencing) = Percentage SNP identified when sequencing data for each sample was assigned a
219 lineage by Pangolin.

220 The mutation assay cannot distinguish what the substitution is in 'ref/mut' results, which highlights
221 the continued importance of sequencing and updating SNP mutations which can be added when
222 designing an assay panel. The mutation assay cannot be used to identify variant lineages, however it
223 can, due to the detection of specific mutations, give an indication as to which variant the sample may
224 be and can also exclude the presence of a VOC in a sample based on the absence of key characterising
225 mutations of significance. This is of particular importance as case numbers rise, and sequencing
226 capacity and turnaround time may not be matched. Specifically for VOC Alpha (B.1.1.7) ref/mut
227 further analysis of genome sequencing data revealed that this variant, although negative for P681R,
228 was positive for P681H. Importantly, it was noted that one ref/mut was also positive for E484K and


229 clarification from the University of Birmingham arm of the COG UK consortium confirmed that this
230 was a small cluster of B.1.1.7 variants that was being monitored and actioned in the Birmingham area.

231 **The Mutation Panel Assay is highly adaptable to newly emerging variants and mutations**

232 The mutation panel designed for this assay was to identify samples containing SNPs associated with
233 variants of SARS-CoV-2 widely circulating within the United Kingdom March 2021- May 2021, this
234 included mutations found in the table 2. Between April and May B.1.617 variant numbers were
235 increasing rapidly and beginning to overtake the B.1.1.7 variant within the UK population. Therefore,
236 as experiments were being conducted in real-time the addition of P618R and L452R assays were
237 essential for rapid identification of B.1.617 variants. Samples that had previously been run for the
238 original assays and sent for sequencing meant that RNA availability was limited. However, freshly
239 isolated samples from May provided the opportunity to run all assays at once.

240 186 samples were assayed with 182 run for N501Y, 183 for E484K and 178 for K417N, and a total of
241 42 samples were assayed for all 5 mutations; 68.7% of samples assayed were positive for N501Y (WT
242 ref/ref = 31.3%); 2% of samples were positive for E484K (WT ref/ref = 97.2%); 2.8% of samples assayed
243 were positive for K417N (WT ref/ref = 97.2%) ; 57.1% of samples were positive for L425R (WT ref/ref
244 = 42.9%) and 61% were positive for P681R (WT ref/ref = 19%). A ref/mut 'call' was also noted for E484K
245 (1 sample, 0.6%) and P681R (8 samples, 19%).

246 Lineage was identifiable in 76.8% (Figure 6) of samples sent for sequencing, which as mentioned
247 previously may be due to the sequencing platform used and/or RNA quality. From our pool of samples,
248 65% of samples were the B.1.1.7 variant, 22% B.1.617.2, 4% B.1.177, 2% B.1.137, 1.3% B.1.351 and
249 B.52 with B.1.177.16, B.1.1.372, B.1.1 and B.1 variants making up 2.7%. Cases of B.1.617.2 were first
250 identified at the end of April 2021.



251

252

253 **Figure 6.** Lineage of sequenced samples identified by Pangolin. **(A)** Number of samples assigned a SARS CoV-2
 254 lineage. **(B)** Percentage of samples assigned a lineage as compared to the total number of samples assigned a
 255 lineage.

256 Discussion

257 Genomic epidemiology is a powerful tool for tracking transmission and importation of SARS-CoV-2 as
 258 well as assessing the effectiveness of public health measures (**1, 2, 3**). Tracking transmission within
 259 the population in real-time enables laboratories to report and governments to action. Recently,
 260 Thermo Fisher have developed genotyping assays to help bridge the gap between testing capacity and
 261 sequencing capability to receive results in real-time. A previous study from our laboratory
 262 demonstrated that B.1.1.7 was associated with significantly higher viral loads (**17**) and had a
 263 genotyping assay been available at the time, this would have helped to identify the Alpha variant much
 264 quicker and identify speed and spread of infection for quicker action and containment.

265 In our laboratory, an opportunity arose to genotype RNA extracted in real-time from Birmingham Trust
266 Hospital, Pillar 2 and University of Birmingham Lateral Flow, positive SARS-CoV-2 samples. Initially
267 using three verified SNP assays from Thermo Fisher's Applied Biosystems™ TaqMan™ SARS-CoV-2
268 Mutation Panel and then expanding to five to include SNPS for the delta variant, we matched
269 genotypes for specific mutations in variants Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2).

270 Here we demonstrate that these mutation panels provide robust detection of VOC even if RNA is of
271 low quality and after more than one freeze/thaw step. Importantly, a specific mutation can be
272 identified on the same day that a nasopharyngeal swab tests positive by RT-PCR. Where sequencing
273 data was available, the genotyping assay always matched 100% to the correct lineage.

274 The ref/mut function is a key to the genotyping assay as when detected this will imply an amino acid
275 change for the specific mutation at the genomic site where the primers amplify. This is crucial in
276 alerting to the potential rise of a new VOI (variants of interest) so it can be monitored to see its
277 potential to become a VOC.

278 Our study confirms that same day rapid real-time detection of variants present in the population is
279 very achievable - from a swab entering the lab, processing through the TaqPath COVID-19 RT-PCR and
280 mutation assay, where results were then available in approximately 5 hours. Confirmation of
281 mutations present and lineage identification following genomic sequencing on-site was provided in
282 approximately 72hours, however, when on-site sequencing is not available this may increase
283 turnaround time significantly. Rapid identification of VOCs enables test-and-trace to identify regional
284 clusters and perform targeted testing to prevent spread of more transmissible variants. Having both
285 PCR set-ups in our modular testing system and on-site sequencing removes the logistics, costs and
286 time of moving samples between testing labs and sequencing labs and reporting the results.

287 Importantly, the genotyping panel can be updated readily as new SNP mutations are identified via
288 genome sequencing data from COG-UK. Delta variants emerged quickly over a few weeks and during

289 our study we were able to source very quickly, two mutation panels for the Delta variant (L452R and
290 P681R) and on arrival were able to action on the same day.

291 Genome sequencing can be inconclusive for identifying key mutations found by the mutation panels
292 but nonetheless, it is a powerful tool for identifying SARS-CoV-2 variant lineages through phylogenetic
293 trees. However, previous studies have discussed there are limitations due to sequence drop-out when
294 used to identify specific key mutations (**18, 19, 20, 21**). Nanopore sequenced long-reads can be
295 susceptible to errors where identifying specific mutations may be problematic. These allelic drop-outs
296 potentially affect PCR-based (tile amplicon) targeted sequencing, thus resulting in incomplete genome
297 coverage, especially at lower amounts, resulting in the loss of both 5' and 3' regions that fall outside
298 primer binding positions. The presence of SNPs in the forward and / or reverse primer binding sites
299 may lead to complete or partial lack of amplification.

300 For the study presented here, we demonstrated that genotyping has two major functions. 1)
301 Genotyping is a powerful additional, more in-depth assay for identifying specific mutations and has
302 real clinical health value allowing laboratories to report and action VOC much quicker than genome
303 sequencing. 2) Genotyping is an excellent additional complement to the already powerful tool of
304 genome sequencing already proven for assigning lineages via phylogenetic trees.

305 Our data confirms that SARS-CoV-2 genotyping is essential for real-time identification of VOC here
306 now and tracking those that emerge for informing public health strategy.

307 **Acknowledgements**

308 Reagents and technical assistance for this study were provided free of charge by Jelena Feenstra,
309 Tamra Hill and Manoj Ghandi at Thermo Fisher. Thermo Fisher had no influence or role in study design,
310 data analysis, data interpretation or construction of the manuscript. The UoB Turnkey Covid diagnostic
311 lab was created wholly from funds directly attributed by DHSC. COG-UK is supported by funding from
312 the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute

313 of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as
314 the Wellcome Sanger Institute.

315 **References**

- 316 1. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune
317 escape. *Nat Rev Microbiol* **2021**; 19, 409-424.
- 318 2. Voltz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in
319 England. *Nature* **2021**; 593 266-269.
- 320 3. Mishra M, Mindermann M, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and
321 rise of Delta variant in England. *EclinicalMedicine* **2021**; 39:101064.
- 322 4. McNally, A. What makes new variants of SARS-CoV-2 concerning is not where they come from,
323 but the mutations they contain. *BMJ* **2021**; 372.
- 324 5. Public Health England. Investigation of SARS-CoV-2 variants of concern: technical briefings.
325 [https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201)
326 [of-concern-20201201](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201)
- 327 6. Richter, A, Plant T, Kidd M, et al. How to establish an academic SARS-CoV-2 testing laboratory. *Nat*
328 *Microbiol* **2020**; 5, 1452–1454.
- 329 7. Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-
330 CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological.org*. Available
331 from: [https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/1)
332 [lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/1](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/1)
- 333 8. Meng B, Kemp SA, Papa G, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and
334 its role in the Alpha variant B.1.1.7. *Cell Reports* **2021**; 35(13):109292.
- 335 9. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 10.
336 7th May **2021**.

- 337 10. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data
338 [/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf)
- 339 11. COVID-19 Genomics UK (COG-UK). An integrated national scale SARS-CoV-2 genomic surveillance
340 network. *Lancet Microbe* **2020**; 1(3):e99–e100.
- 341 12. ThermoFisher. MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit.
342 <https://www.thermofisher.com/order/catalog/product/A48383>
- 343 13. ThermoFisher TaqPath COVID-19 RT-PCR testing kit. Available online from:
344 <https://www.thermofisher.com/order/catalog/product/A48067>
- 345 14. Thermo Fisher TaqMan™ SARS-CoV-2 Mutation Panel User Guide.
346 [https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0024768_TaqManSARS-CoV-](https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0024768_TaqManSARS-CoV-2_MutationPanel_UG.pdf)
347 [2_MutationPanel_UG.pdf](https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0024768_TaqManSARS-CoV-2_MutationPanel_UG.pdf)
- 348 15. Quick J. nCoV-2019 sequencing protocol v3 (LoCost). protocols.io 2020.
349 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>
- 350 16. ARTIC Network. ARTIC Nanopore protocol for nCoV2019 novel coronavirus. GitHub.
351 <https://github.com/artic-network/artic-ncov2019>
- 352 17. Loman N, Rowe W, Rambaut A. et al. nCoV-2019 novel coronavirus bioinformatics protocol.
353 ARTICnetwork 2020. <https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html>
- 354 18. Kidd M, Richter A, Best A, et al. S-Variant SARS-CoV-2 Lineage B.1.1.7 Is Associated With
355 Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction. *J Infect*
356 *Dis* **2021**; 223(10):1666-1670.
- 357 19. Quick J, Loman N, Duraffour S, et al. Real-time, portable genome sequencing for Ebola
358 surveillance. *Nature* **2016**; 530, 228–232.
- 359 20. Vasudevan K, Ragupathi NKD, Jacob JJ, et al. Highly accurate-single chromosomal complete
360 genomes using IonTorrent and MinION sequencing of clinical pathogens. *Genomics* **2020**;
361 112:545-551.

- 362 21. Rang FJ, Cloosterman WP, de Ridder J. From squiggle to basepair: computational approaches for
363 improving nanopore sequencing read accuracy. *Genome Biol* 2018; 19 (1): 90.
- 364 22. Grubaugh N.D, Gangavarapu K, Quick J., et al. An amplicon-based sequencing framework for
365 accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol.* **2019**; **20**:8